Insulet Corp
NASDAQ:PODD
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
161.02
275.7
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Insulet Corp
Insulet Corp
Cost of Revenue
Insulet Corp
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Insulet Corp
NASDAQ:PODD
|
Cost of Revenue
-$607.9m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-15%
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Cost of Revenue
-$11B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-10%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Cost of Revenue
-$4.9B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-8%
|
|
|
Stryker Corp
NYSE:SYK
|
Cost of Revenue
-$7.9B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-9%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Cost of Revenue
-$18.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-7%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cost of Revenue
-$2.6B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-14%
|
|
Insulet Corp
Glance View
Insulet Corporation has carved out a significant niche in the medical device industry, distinguishing itself through its innovative approach to diabetes management. The company is best known for its Omnipod Insulin Management System, a discreet, tubeless insulin pump that provides a solution for individuals with diabetes seeking an alternative to traditional insulin delivery methods. Unlike conventional pumps that require cumbersome tubes and significant patient involvement, the Omnipod system offers ease and convenience, allowing users more freedom and flexibility in their daily lives. The system operates via a small wearable pod that delivers insulin over several days, which users control remotely, removing much of the hassle associated with managing diabetes. Insulet generates revenue by selling these pods and the associated Personal Diabetes Manager (PDM) devices, which together comprise the entire system. Customers typically purchase pods on a recurring basis, similar to a subscription model, which creates a steady stream of revenue for the company. The business model emphasizes continuous growth by expanding its user base and improving its technology to remain at the forefront of patient-centric diabetes care. Insulet's strategic focus on the needs of its users and commitment to refining their health technology has enabled it to build a sustainable business that addresses a critical healthcare challenge while also delivering consistent financial performance.
See Also
What is Insulet Corp's Cost of Revenue?
Cost of Revenue
-607.9m
USD
Based on the financial report for Sep 30, 2024, Insulet Corp's Cost of Revenue amounts to -607.9m USD.
What is Insulet Corp's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-15%
Over the last year, the Cost of Revenue growth was -12%. The average annual Cost of Revenue growth rates for Insulet Corp have been -22% over the past three years , -21% over the past five years , and -15% over the past ten years .
You don't have any saved screeners yet
